Document is current
Any future updates will be listed below
-
Authors
You, Shoujiang
Zheng, Danni
Wang, Yanan
Li, Qiang
Nguyen, Tu N.
Peters, Ruth
Chen, Xiaoying
Wang, Xia
Cao, Yongjun
Grobbee, Diederick E.
Harrap, Stephen
Mancia, Giuseppe
Williams, Bryan
Poulter, Neil R.
Lisheng, Liu
Marre, Michel
Hamet, Pavel
Anderson, Craig S.
Woodward, Mark
Chalmers, John
Harris, Katie
- License Information
-
More Information
Article History
Received: 25 September 2024
Accepted: 7 February 2025
First Online: 12 February 2025
Declarations
:
: Ethics approval came from the institutional review board of each center as outlined in:• Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829–840.• Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–2572.All participants provided written informed consent to participate in ADVANCE.
: This study was approved for publication by the ADVANCE Management Committee.
: SY holds China Scholarship Council (CSC) grant, the National Natural Science Foundation of China (82471226), Jiangsu Provincial Medical Key Discipline (ZDXK202217) and the 6th Jiangsu Province 333 High Level Talents Training Project. JC reports research grants from the NHMRC and from Servier International for the ADVANCE trial and the ADVANCE-ON follow-up study, all before 2014. MW also reports research support from the NHMRC, as well as consultancy work for Freeline in the recent past. CSA holds a Senior Investigator Fellowship of the NHMRC and reports receipt of advisory board fees from AstraZeneca, Australia. GM has received compensations as speaker/chairman/consultant from: Berlin Chemie, IPCA Laboratories, Medtronic Inc USA, Menarini Int, Merck Healthcare KGaA, Omnicuris, Recordati, Sanofi, Servier, Sun Laboratories. NP has received personal speaker fees from Servier, Takeda and Novo Nordisk, and advisory board activities from AstraZeneca and Novo Nordisk, and has received grants for his research group relating to diabetes mellitus from Diabetes UK, NIHR Efficacy and Mechanism Evaluation Programme (EME), Julius Clinical and the British Heart Foundation with a pending grant from Novo Nordisk. N.P. holds no stocks or shares in any such companies All other authors declare that they have no competing interest.
